Clinical trial
A Multi-Center, Randomised, Double-blind, Placebo Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
NCT06007014 is registered in ClinicalTrials.gov with Yanbing Li as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomised, Double-blind, Placebo Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
- Lead sponsor
- Yanbing Li
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 31, 2023
- Completion date
- December 30, 2025
- Enrollment
- 128 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
128 patients were randomly assigned 1:1, changes in hba1c from baseline at 18 weeks of treatment, efficacy and safety of chiglitazar sodium in the treatment of t2dm patients, investigatorinitiate trial, metformin and insulin glargine combined with chiglitazar sodium tablets 48mg/ day group, metformin and insulin glargine combined with placebo group, metformin combined with insulin glargine in the treatment of type 2 diabetes patients who still have poor hypoglycemic effect